Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Asymptomatic Multiple Myeloma
NCT02784483Phase 1Terminated
- Sponsor
- Yale University
- Start
- Feb 2017
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab in multiple myeloma (MM), sponsored by Yale University. Primary endpoint: Prevalence of anti-SOX2 reactive T cells at 1 year. Started Feb 2017; status: terminated.
02
Drugs
atezolizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02784483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784483.